Summary of Product Characteristics

1. Name of the medicinal product

AZID 250 mg film-coated Tablets
AZID 500 mg film-coated Tablets
azithromycin

2. Qualitative and quantitative composition

Each film-coated tablet contains 500 mg AZID (as AZID monohydrate).
For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Film-coated tablet.
.

4. Clinical particulars

4.1 Therapeutic indications

AZID is indicated for the treatment of the following infections, when caused by microorganisms sensitive to AZID (see section 4.4 and 5.1):
• Acute bacterial sinusitis (adequately diagnosed)
• Acute bacterial otitis media (adequately diagnosed)
• Pharyngitis, tonsillitis
• Acute exacerbation of chronic bronchitis (adequately diagnosed)
• Mild to moderately severe community acquired pneumonia
• Infections of the skin and soft tissues of mild to moderate severity e.g. folliculitis, cellulitis, erysipelas
• Uncomplicated Chlamydia trachomatis urethritis and cervicitis
Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2 Posology and method of administration

Posology
AZID tablets should be given as a single daily dose. The duration of treatment in each of the infectious diseases is given below.

Adults, elderly, children and adolescents over 45 kg body weight
The total dosage of AZID is 1500 mg which is spread over three days (500 mg once daily).
Alternatively, the dosage can be spread over five days (500 mg as a single dose on the first day and thereafter 250 mg once daily).
In uncomplicated *Chlamydia trachomatis* urethritis and cervicitis the dosage is 1000 mg as a single oral dose.
For sinusitis, treatment is indicated for adults and adolescents 16 years of age and over.
Children and adolescents 45 kg and under body weight
Tablets are not indicated for these patients. Other pharmaceutical forms of AZID, e.g. suspensions may be used.
Elderly
No dose adjustments are required for elderly patients. Since elderly patients can be patients with ongoing proarrhythmic conditions a particular caution is recommended due to the risk of developing cardiac arrhythmia and torsades de pointes (see section 4.4).
Patients with renal impairment
No dose adjustment is necessary in patients with mild to moderate renal impairment (GFR 30-80 ml/min/1.73 m^2) (see section 4.4).
Patients with hepatic impairment
A dose adjustment is not necessary for patients with mild to moderately impaired liver function (Child-Pugh class A or B) (see section 4.4).

Method of administration
For oral use.
The tablets can be taken with or without food.

4.3 Contraindications

Hypersensitivity to the active substance, to erythromycin or any macrolide or ketolide antibiotic.or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Allergic reactions
As with erythromycin and other macrolides, rare serious allergic reactions including angioneurotic oedema and anaphylaxis (rarely fatal) have been reported alongside dermatological reactions, including acute generalised exanthematous pustulosis (AGEP), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) (rarely fatal) and DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms). A certain number of these reactions resulted in recurring symptoms and required an extended period of observation and treatment.
If an allergic reaction occurs, use of this medicinal product must be discontinued and the appropriate treatment initiated. Doctors must be aware that allergic symptoms can recur if symptomatic treatment is discontinued.

Renal impairment
No dose adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance > 40 ml/min). In patients with severe renal function impairment (GFR < 10 mL/min), a 33% increase in systemic exposure to AZID has been observed (see section 5.2).

Hepatic impairment
Since liver is the principal route of elimination for AZID, the use of AZID should be undertaken with caution in patients with significant hepatic disease. Cases of fulminant hepatitis potentially leading to life-threatening liver failure have been reported with AZID (see section 4.8). Some patients may have, or have had pre-existing hepatic disease or may have been taking other hepatotoxic medicinal products.
In case of signs and symptoms of liver dysfunction, such as rapid developing asthenia associated with jaundice, dark urine, bleeding tendency or hepatic encephalopathy, liver function tests/ investigations should be performed immediately. AZID administration should be stopped if liver dysfunction has emerged.
Liver function disorders, hepatitis, cholestatic jaundice, liver necrosis and renal failure have been reported and have been fatal in a number of cases. Discontinue the use of AZID if signs and symptoms of hepatitis occur.
Pseudomembranous colitis has been reported following use of macrolide antibiotics. This diagnosis should therefore be taken into consideration in patients who develop diarrhoea after starting treatment with AZID.

Infantile hypertrophic pyloric stenosis
Following the use of AZID in neonates (treatment up to 42 days of life), infantile hypertrophic pyloric stenosis (IHPS) has been reported. Parents and caregivers should be informed to contact their physician if vomiting or irritability with feeding occurs.

Ergot alkaloids and AZID
The concurrent use of ergot alkaloids and macrolide antibiotics has been found to accelerate the development of ergotism. The interactions between ergot alkaloids and AZID have not been studied. The development of ergotism is however possible, so that AZID and ergot alkaloid derivatives should not be administered simultaneously.

QT prolongation
Prolonged cardiac repolarisation and a prolonged QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been seen in treatment with other macrolides including AZID (see section 4.8).

Therefore, as the following situations may lead to an increased risk for ventricular arrhythmias (including torsade de pointes) which can lead to cardiac arrest, AZID should be used with caution in patients with ongoing proarrhythmic conditions (especially women and elderly patients) such as:
• Patients with congenital or documented acquired QT prolongation.
• Patients currently receiving treatment with other active substances that prolong QT interval such as antiarrhythmics of class IA (quinidine and procainamide) and class III (dofetilide, amiodarone and sotalol), cisapride and terfenadine; antipsychotic agents such as pimozide; antidepressants such as citalopram; and fluoroquinolones such as moxifloxacin and levofloxacin (see section 4.5).
• Patients with a disrupted electrolyte balance, particularly in cases of hypokalaemia and hypomagnesaemia
• Patients with clinically relevant bradycardia, cardiac arrhythmia or severe cardiac insufficiency.

Myasthenia gravis and AZID
Exacerbations of the symptoms of myasthenia gravis and new onset of myasthenia syndrome have been reported in patients receiving AZID therapy (see section 4.8).

Superinfections
As with any antibiotic preparation, observation for signs of superinfection with non-susceptible organisms, including fungi is recommended.
Clostridium difficile associated diarrhoea
Clostridium difficile associated diarrhoea (CDAD) has been reported with use of nearly all antibacterial agents, including AZID, and may range in severity from mild diarrhoea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*.
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhoea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

The following should be considered before prescribing AZID:
AZID film-coated tablets are not suitable for treatment of severe infections where a high concentration of the antibiotic in the blood is rapidly needed.
As for other macrolides, high resistance rates of *Streptococcus pneumoniae* have been reported for AZID in some European countries (see section 5.1). This should be taken into account when treating infections caused by *Streptococcus pneumoniae*.
The main causative agent of soft tissue infections, *Staphylococcus aureus*, is frequently resistant to AZID. Therefore, susceptibility testing is considered a precondition for treatment of soft tissue infections with AZID.

Pharyngitis/tonsillitis
AZID is not the substance of first choice for the treatment of pharyngitis and tonsillitis caused by *Streptococcus pyogenes*. For this and for the prophylaxis of acute rheumatic fever penicillin is the treatment of first choice.

Sinusitis
Often, AZID is not the substance of first choice for the treatment of sinusitis.

Acute otitis media
Often, AZID is not the substance of first choice for the treatment of acute otitis media.

Infected burn wounds
AZID is not indicated for the treatment of infected burn wounds.

Sexually transmitted disease
In case of sexually transmitted diseases a concomitant infection by *T. pallidum* should be excluded.

Neurological or psychiatric diseases
AZID should be administered with caution to patients suffering from neurological or psychiatric diseases.

Long-term use
There is no experience regarding the safety and efficacy of long-term use of AZID for the mentioned indications. In case of rapid recurrent infections, treatment with another antibiotic should be considered. Due to cross-resistance existing among macrolides, in areas with a high incidence of erythromycin resistance, it is especially important to take into consideration the evolution of the pattern of susceptibility to AZID and other macrolides (see section 5.1).
AZID is not the first choice for the empirical treatment of infections in areas where the prevalence of resistant isolates is 10% or more (see section 5.1).

Paediatric population
Safety and efficacy for the prevention or treatment of Mycobacterium Avium Complex in children have not been established.

This medicinal product contains soya oil
AZID contains soya oil. Patients who are allergic to peanut or soya, must not use this medicinal product.
AZID contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.

4.5 Interaction with other medicinal products and other forms of interaction

Antacids
When studying the effect of simultaneously administered antacid on the pharmacokinetics of AZID, no overall change has been observed in the bioavailability, although the peak concentrations of AZID measured in the plasma reduced by approximately 25 %. In patients receiving both AZID and antacids, the drugs should not be taken simultaneously. AZID should be taken at least 1 hour before or 2 hours after the antacid.
Cetirizine
In healthy volunteers, coadministration of a 5-day regimen of AZID with cetirizine 20 mg at steady-state resulted in no pharmacokinetic interaction and no significant changes in the QT interval.
Didanosine (Dideoxyinosine)
Coadministration of 1200 mg/day AZID with 400 mg/day didanosine in 6 HIV-positive subjects did not appear to affect the steady-state pharmacokinetics of didanosine as compared with placebo.
Digoxin and colchicine (P-gp substrates)
Concomitant administration of macrolide antibiotics, including AZID, with P-glycoprotein substrates such as digoxin and colchicine, has been reported to result in increased serum levels of the P-glycoprotein substrate. Therefore, if AZID and P-gp substrates such as digoxin are administered concomitantly, the possibility of elevated serum concentrations of the substrate should be considered. During treatment with AZID and after discontinuation, clinical monitoring, and possible follow-up of serum digoxin levels, is required.
Zidovudine
Single 1000 mg doses and multiple 1200 mg or 600 mg doses of AZID had little effect on the plasma pharmacokinetics or urinary excretion of zidovudine or its glucuronide metabolite. However, administration of AZID increased the concentrations of phosphorylated zidovudine, the clinically active metabolite, in peripheral blood mononuclear cells. The clinical significance of this finding is unclear, but it may be of benefit to patients.
AZID does not interact significantly with the hepatic cytochrome P450 system. It is not believed to undergo the pharmacokinetic drug interactions as seen with erythromycin and other macrolides. Hepatic cytochrome P450 induction or inactivation via cytochrome-metabolite complex does not occur with AZID.
Ergot derivatives
Due to the theoretical possibility of ergotism, the concurrent use of AZID with ergot derivatives is not recommended (see section 4.4).
Pharmacokinetic studies have been conducted between AZID and the following medicinal products known to undergo significant cytochrome P450 mediated metabolism.

Astemizole and alfentanil
No data are available on interactions with astemizole and alfentanil. Caution should be exercised with concomitant use of these agents and AZID in view of the described potentiation of its effect during concomitant use of the macrolide antibiotic erythromycin.
Atorvastatin
Coadministration of atorvastatin (10 mg daily) and AZID (500 mg daily) did not alter the plasma concentrations of atorvastatin (based on a HMG CoA-reductase inhibition assay). However, post-marketing cases of rhabdomyolysis in patients receiving AZID with statins have been reported.
Carbamazepine
In a pharmacokinetic interaction study in healthy volunteers, no significant effect was observed on the plasma levels of carbamazepine or its active metabolite in patients receiving concomitant AZID.
Cisapride
Cisapride is metabolised in the liver by the enzyme CYP 3A4. Because macrolides inhibit this enzyme, concomitant administration of cisapride may cause the increase of QT interval prolongation, ventricular arrhythmias and torsades de pointes.
Cimetidine
In a pharmacokinetic study investigating the effects of a single dose of cimetidine, given 2 hours before AZID, on the pharmacokinetics of AZID, no alteration of AZID pharmacokinetics was seen.
Coumarin-Type Oral Anticoagulants
In a pharmacokinetic interaction study, AZID did not alter the anticoagulant effect of a single 15 mg dose of warfarin administered to healthy volunteers. There have been reports received in the post-marketing period of potentiated anticoagulation subsequent to coadministration of AZID and coumarin type oral anticoagulants. Although a causal relationship has not been established, consideration should be given to the frequency of monitoring prothrombin time when AZID is used in patients receiving coumarin-type oral anticoagulants.
Ciclosporin
In a pharmacokinetic study with healthy volunteers that were administered a 500 mg/day oral dose of AZID for 3 days and were then administered a single 10 mg/kg oral dose of ciclosporin, the resulting ciclosporin C_{max} and AUC_{0-5} were found to be significantly elevated. Consequently, caution should be exercised before considering concurrent administration of these medicinal products. If coadministration of these medicinal products is necessary, ciclosporin levels should be monitored and the dose adjusted accordingly.
Efavirenz
Coadministration of a 600 mg single dose of AZID and 400 mg efavirenz daily for 7 days did not result in any clinically significant pharmacokinetic interactions.
Fluconazole
Coadministration of a single dose of 1200 mg AZID did not alter the pharmacokinetics of a single dose of 800 mg fluconazole. Total exposure and half-life of AZID were unchanged by the coadministration of fluconazole, however, a clinically insignificant decrease in C_{max} (18%) of AZID was observed.
Indinavir
Coadministration of a single dose of 1200 mg AZID had no statistically significant effect on the pharmacokinetics of indinavir administered as 800 mg three times daily for 5 days.
Methylprednisolone
In a pharmacokinetic interaction study in healthy volunteers, AZID had no significant effect on the pharmacokinetics of methylprednisolone.
Midazolam
In healthy volunteers, coadministration of AZID 500 mg/day for 3 days did not cause clinically significant changes in the pharmacokinetics and pharmacodynamics of a single 15 mg dose of midazolam.
Nelfinavir
Coadministration of AZID (1200 mg) and nelfinavir at steady state (750 mg three times daily) resulted in increased AZID concentrations. No clinically significant adverse effects were observed and no dose adjustment is required.
Rifabutin
Coadministration of AZID and rifabutin did not affect the serum concentrations of either active. Neutropenia was observed in subjects receiving concomitant treatment of AZID and rifabutin. Although neutropenia has been associated with the use of rifabutin, a causal relationship to combination with AZID has not been established (see section 4.8).

Sildenafil
In normal healthy male volunteers, there was no evidence of an effect of AZID (500 mg daily for 3 days) on the AUC and C_{max}, of sildenafil or its major circulating metabolite.
Terfenadine
Pharmacokinetic studies have reported no evidence of an interaction between AZID and terfenadine. There have been rare cases reported where the possibility of such an interaction could not be entirely excluded; however there was no specific evidence that such an interaction had occurred.
Theophylline
There is no evidence of a clinically significant pharmacokinetic interaction when AZID and theophylline are co-administered to healthy volunteers.
Triazolam
In 14 healthy volunteers, coadministration of AZID 500 mg on Day 1 and 250 mg on Day 2 with 0.125 mg triazolam on Day 2 had no significant effect on any of the pharmacokinetic variables for triazolam compared to triazolam and placebo.
Trimethoprim/sulfamethoxazole
Coadministration of trimethoprim/sulfamethoxazole DS (160 mg/800 mg) for 7 days with AZID 1200 mg on Day 7 had no significant effect on peak concentrations, total exposure or urinary excretion of either trimethoprim or sulfamethoxazole. AZID serum concentrations were similar to those seen in other studies.
Protease inhibitors
There are no data available about a possible interaction with protease inhibitors.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no adequate data from use of AZID in pregnant women. In reproduction toxicity studies in animals, AZID was shown to pass the placenta, but no teratogenic effects were observed. The safety of AZID has not been confirmed with regard to the use of the active substance during pregnancy. Therefore, AZID should only be used during pregnancy if the benefit outweighs the risk.

Breast-feeding
AZID passes into human breast milk, but there are no adequate and well-controlled clinical studies in nursing women that have characterised the pharmacokinetics of AZID excretion into human breast milk. Because it is not known whether AZID may have adverse effects on the breast-fed infant, nursing should be discontinued during treatment with AZID. Among other things diarrhoea, fungus infection of the mucous membrane as well as sensitisation is possible in the nursed infant. It is recommended to discard the milk during treatment and up until 2 days after discontinuation of treatment. Nursing may be resumed thereafter.

Fertility
In fertility studies conducted in rat, reduced pregnancy rates were noted following administration of AZID. The relevance of this finding to humans is unknown.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. However, the possibility of undesirable effects like dizziness and convulsions should be taken into account when performing these activities.

4.8 Undesirable effects

The table below lists the adverse reactions identified through clinical trial experience and post-marketing surveillance by system organ class and frequency The frequency grouping is defined using the following convention: Very common (≥1/10); Common (≥ 1/100 to <1/10); Uncommon (≥1/1,000 to <1/100); Rare (≥ 1/10,000 to <1/1,000); Very Rare (< 1/10,000); and Not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

	Very Common	Common	Uncommon	Rare	Very rare	Not Known
Infections and Infestations			Candidiasis, vaginal infection, pneumonia, fungal infection, bacterial infection, pharyngitis, gastroenteritis, respiratory disorder, rhinitis, oral candidiasis			Pseudomembranous colitis (see section 4.4)
Blood and Lymphatic System Disorders			Leukopenia, neutropenia, eosinophilia			Thrombocytopenia, haemolytic anaemia
Immune System Disorders			Angioedema, hypersensitivity			Anaphylactic reaction (see section 4.4)
Metabolism and Nutrition Disorders			Anorexia			
Psychiatric Disorders			Nervousness, insomnia	Agitation Irritability		Aggression, anxiety, delirium, hallucination
Nervous System Disorders		Headache, dizziness, somnolence, dysgeusia, paraesthesia	Hypoaesthesia			Syncope, convulsion, psychomotor hyperactivity, anosmia, ageusia, parosmia, myasthenia gravis (see section 4.4)
Eye Disorders		Visual impairment				
Ear and Labyrinth Disorders		Deafness	Ear disorder, vertigo, hearing impairment including hearing loss, tinnitus			

Cardiac Disorders			Palpitations			Torsades de pointes (see section 4.4), arrhythmia (see section 4.4) including ventricular tachycardia, Electrocardiogram QT prolonged (see section 4.4)
Vascular Disorders			Hot flushes			Hypotension
Respiratory, thoracic and mediastinal disorders			Dyspnoea, epistaxis			
Gastrointestinal Disorders	Diarrhoea, abdominal pain, nausea, flatulence	Vomiting, dyspepsia	Constipation, gastritis, dysphagia, abdominal distension, dry mouth, eructation, mouth ulceration, salivary hypersecretion			Pancreatitis, tongue discolouration, tooth discolouration
Hepatobiliary Disorders			Hepatitis, abnormal hepatic function	Cholestatic jaundice		Hepatic failure (which has rarely resulted in death) (see section 4.4), fulminant hepatitis, hepatic necrosis
Skin and Subcutaneous Tissue Disorders		Rash, pruritus	Urticaria, dermatitis, dry skin, hyperhidrosis, Stevens-Johnson syndrome, Photosensitivity reaction	, Acute generalised exanthematous pustulosis (AGEP)	DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms)	Toxic epidermal necrolysis, erythema multiforme
Musculoskeletal and Connective Tissue Disorders		Arthralgia	Osteoarthritis, myalgia, back pain, neck pain			

Renal and Urinary Disorders			Dysuria, renal pain			Acute renal failure, interstitial nephritis
Reproductive system and breast disorders			Metrorrhagia, testicular disorder			
General Disorders and Administration Site Conditions		Fatigue	Oedema, asthenia, malaise, face oedema, chest pain, pyrexia, pain, peripheral oedema			
Investigations		Lymphocyte count decreased, eosinophil count increased, blood bicarbonate decreased, basophils increased, monocytes increased, neutrophils increased	Aspartate aminotransferase increased, alanine aminotransferase increased, blood bilirubin increased, blood urea increased, blood creatinine increased, blood potassium abnormal, blood alkaline phosphatase increased, chloride increased, glucose increased, platelets increased, haematocrit decreased, bicarbonate increased, abnormal sodium			
Injury, poisoning and procedural complications			Post procedural complication			

Adverse reactions possibly or probably related to AZID based on clinical trial experience and post-marketing surveillance:
Adverse reactions possibly or probably related to Mycobacterium Avium Complex prophylaxis and treatment based on clinical trial experience and post-marketing surveillance. These adverse reactions differ from those reported with immediate release or the prolonged release formulations, either in kind or in frequency:

	Very Common	Common	Uncommon
Metabolism and Nutrition Disorders		Anorexia	
Nervous System Disorders		Dizziness, headache, paraesthesia, dysgeusia	Hypoaesthesia
Eye Disorders		Visual impairment	
Ear and Labyrinth Disorders		Deafness	Hearing impaired, tinnitus
Cardiac Disorders			Palpitations
Gastrointestinal Disorders	Diarrhoea, abdominal pain, nausea, flatulence, abdominal discomfort, loose stools		
Hepatobiliary Disorders			Hepatitis
Skin and Subcutaneous Tissue Disorders		Rash, pruritus	Stevens-Johnson syndrome, photosensitivity reaction
Musculoskeletal and Connective Tissue Disorders		Arthralgia	
General Disorders and Administration Site Conditions		Fatigue	Asthenia, malaise

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important.

4.9 Overdose

Adverse events experienced in higher than recommended doses were similar to those seen at normal doses. Characteristic symptoms of overdose with macrolide antibiotics include the following: reversible hearing loss, severe nausea, vomiting and diarrhoea.
In the event of overdosage, general symptomatic and supportive measures are indicated as required.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antibacterials for systemic use; macrolides, ATC Code: J01FA10.
AZID is a macrolide antibiotic belonging to the azalide group.
The molecule is constructed by adding a nitrogen atom to the lactone ring of erythromycin A. The chemical name of AZID is 9-deoxy-9a-aza-9a-methyl-9a-homo-erythromycin A. The molecular weight is 749.0.

Mechanism of action
AZID avoids the translocation of peptide chains from one side of the ribosome to the other by binding to the 50S ribosomal subunit. As a result, RNA-dependent protein synthesis in susceptible organisms is inhibited.

Cardiac electrophysiology :
QTc interval prolongation was studied in a randomised, placebo-controlled parallel trial in 116 healthy subjects, who received chloroquine (1000 mg), either alone or in combination with AZID (500 mg, 1000 mg and 1500 mg once daily). Concomitant administration of AZID increased the QTc interval in a dose and concentration-dependent manner. Compared to chloroquine alone, the maximum mean (95% upper confidence bound) increases in QTcF were 5 (10) ms, 7 (12) ms and 9 (14) ms with concomitant administration of 500 mg, 1000 mg and 1500 mg AZID, respectively.

Mechanism of resistance
The two most frequently encountered mechanisms of resistance to macrolides, including AZID, are target modification (most commonly by methylation of 23S rRNA) and active efflux. The occurrence of these resistance mechanisms varies from species to species, and within a single species, the frequency of resistance varies by geographical location.
The most important ribosomal modification that determines reduced binding of macrolides is post-transcriptional (N6)-dimethylation of adenine at nucleotide A2058 (*Escherichia coli* numbering system) of the 23S rRNA by methylases encoded by *erm* (*e*rythromycin *r*ibosome *m*ethylase) genes. Ribosomal modifications often determine cross resistance (MLSB phenotype) to other classes of antibiotics whose ribosomal binding sites overlap those of the macrolides: the lincosamides (including clindamycin), and the streptogramin B (which include, for example, the quinupristin component of quinupristin/dalfopristin). Different *erm* genes are present in different bacterial species, in particular Streptococci and Staphylococci. Susceptibility to macrolides can also be affected by less frequently encountered mutational changes in nucleotides A2058 and A2059, and at some other positions of 23S rRNA, or in the large subunit ribosomal proteins L4 and L22.
Efflux pumps occur in a number of species, including Gram-negatives, such as *Haemophilus influenzae* (where they may determine intrinsically higher MICs) and Staphylococci. In Streptococci and Enterococci, an efflux pump that recognises 14- and 15-membered macrolides (which include, respectively, erythromycin and AZID) is encoded by *mef* (A) genes.
A complete cross-resistance exists among erythromycin, AZID, other macrolides and lincosamides for *Streptococcus pneumoniae*, beta-haemolytic streptococci of group A, *Enterococcus* spp. and *Staphylococcus aureus*, including methicillin-resistant *S. aureus* (MRSA).
A decrease in macrolide susceptibility over time has been noted particularly in *Streptococcus pneumoniae* and *Staphylococcus aureus* and is also observed in Streptococcus viridans and in *Streptococcus agalactiae*.
Penicillin-sensitive *S. pneumoniae* are more likely to be susceptible to AZID than are penicillin-resistant strains of *S. pneumoniae*. Methicillin-resistant *S. aureus* (MRSA) is less likely to be susceptible to AZID than methicillin-sensitive *S. aureus* (MSSA).

Susceptibility test breakpoints:
The EUCAST susceptibility criteria are listed in the table below.
EUCAST Susceptibility Breakpoints for AZID.
EUCAST

	MIC (mg/L)	
Pathogens	**Susceptible**	**Resistant**
Staphylococcus spp.	≤ 1	> 2
Streptococcus spp. (Group A, B, C, G)	≤ 0.25	> 0.5
Streptococcus pneumoniae	≤ 0.25	> 0.5
Haemophilus influenzae	≤ 0.12	> 4
Moraxella catarrhalis	≤ 0.25	> 0.5
Neisseria gonorrhoeae	≤ 0.25	> 0.5

UCAST = European Committee on Antimicrobial Susceptibility Testing; MIC = Minimum inhibiting concentration.

Susceptibility
The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.
Pathogens for which resistance may be a problem: prevalence of resistance is equal to or greater than 10% in at least one country in the European Union.
Table 1: Antibacterial spectrum of AZID

Species
Commonly susceptible species
Aerobic Gram-positive
Corynebacterium diphteriae
Streptococcus pneumoniae
Erythromycin-sensitive
Penicillin-sensitive
Streptococcus pyogenes
Erythromycin-sensitive
Aerobic Gram-negative
Bordetella pertussis
Escherichia coli-ETEC
Escherichia coli-EAEC
Haemophilus influenzae *Haemophilus ducreyi*
Legionella spp.
Moraxella catarrhalis
Erythromycin-sensitive
Erythromycin-intermediate
Pasteurella multocida
Anaerobic
Fusobacterium nucleatum *Fusobacterium necrophorum*
Prevotella spp.
Porphyromonas spp.
Propionibacterium spp.
Other micro-organisms
Chlamydia pneumoniae
Chlamydia trachomatis

Listeria spp.
Mycobacterium avium Complex
Mycoplasma pneumoniae
Species for which acquired resistance may be a problem
Aerobic Gram-positive
Staphylococcus aureus
Methicillin-susceptible
Coagulase-neg. staphylococci
Methicillin-susceptible[+]
Streptococcus pneumoniae
Penicillin-intermediate
Penicillin-resistant
Erythromycin-intermediate
Streptococcus pyogenes
Erythromycin-intermediate
Streptococci viridans group
Penicillin-intermediate
Aerobic Gram-negative
Moraxella catarrhalis Erythromycin-resistant
Anaerobic
Peptostreptococcus spp.
Inherently resistant organisms
Aerobic Gram positive
Corynebacterium spp.
Enterococcus spp.
Staphylococci MRSA, MRSE
Streptococcus pneumoniae
Erythromycin-resistant
Penicillin & Erythromycin resistant
Streptococcus pyogenes
Erythromycin-resistant
Streptococci viridans group
Penicillin-resistant
Erythromycin-resistant

Aerobic Gram-negative
Pseudomonas aeruginosa
Anaerobic
Bacteroides fragilis group

[+] Resistance is greater than 50%.

Following the assessment of studies conducted in children, the use of AZID is not recommended for the treatment of malaria, neither as monotherapy nor combined with chloroquine or artemisinin based drugs, as non-inferiority to anti-malarial drugs recommended in the treatment of uncomplicated malaria was not established.

5.2 Pharmacokinetic properties

Absorption

Following oral administration the bio-availability of AZID is approximately 37%. Peak plasma levels are reached after 2-3 hours. The mean maximum concentration observed (C_{max}) after a single dose of 500 mg is approximately 0.4 µg/ml.

Distribution

Orally administered AZID is widely distributed throughout the body. Pharmacokinetic studies have shown considerably higher AZID concentrations in the tissues (up to 50 times the maximum concentration observed in the plasma). This indicates that the substance is extensively bound in the tissues (steady-state volume of distribution approximately 31 l/kg). The mean maximum observed serum concentration (C_{max}) after a single dose of 500 mg is approx. 0.4 mg/mL, 2-3 hours after administration. With the recommended dosage no accumulation in the serum/plasma occurs. Accumulation does occur in the tissues where the levels are much higher than in the serum/plasma. Three days after administration of 500 mg as a single dose or in split doses, concentrations of 1.3 to 4.8 mg/g, 0.6 to 2.3 mg/g, 2.0 to 2.8 mg/g and 0 to 0.3 mg/mL were detected in lung, prostate, tonsil and serum respectively. Concentrations in these target tissues exceed the MIC90 for likely pathogens.

In experimental *in vitro* and *in vivo* studies, AZID accumulates in phagocytes; release is promoted by active phagocytosis. In animal models this process appears to contribute to the accumulation of AZID in tissue.

The binding of AZID to plasma proteins is variable and varies from 52% at 0.005 µg/ml to 18% at 0.5 µg/ml, depending on the serum concentration.

Biotransformation and Excretion

The terminal plasma elimination half-life follows the tissue depletion half-life of 2 to 4 days.

Approximately 12% of an intravenously administered dose is excreted in unchanged form with the urine over a period of 3 days; the major proportion in the first 24 hours. Concentrations of up to 237 µg/ml AZID, 2 days after a 5-day course of treatment, have been found in human bile, together with 10 metabolites (formed by N- and O-demethylation, by hydroxylation of the desosamine and aglycone rings, and by splitting of the cladinose conjugate). Investigations suggests that the metabolites do not play a role in the micro-biological activity of AZID.

Pharmacokinetics in special populations

Renal impairment

Following a single oral dose of AZID 1g, mean C_{max} and AUC_{0-120} increased by 5.1% and 4.2% respectively, in subjects with mild to moderate renal impairment (glomerular filtration rate of 30-80 ml/min/1.73m^2) compared with normal renal function (GFR > 80 ml/min). In subjects with severe renal impairment (GFR < 30 ml/min/1.73m^2), the mean C_{max} and AUC_{0-120} increased 61% and 35% respectively compared to normal.

Hepatic impairment

In patients with mild to moderate hepatic impairment, there is no evidence of a marked change in serum pharmacokinetics of AZID compared to normal hepatic function. There are no data on AZID use in cases of more severe hepatic impairment.

Elderly

The pharmacokinetics of AZID in elderly men was similar to that of young adults; however, in elderly women, although higher peak concentrations (increased by 30-50%) were observed, no significant accumulation occurred.

In elderly volunteers (>65 years), higher (29 %) AUC values were always observed after a 5-day course than in younger volunteers (<45 years). However, these differences are not considered to be clinically relevant; no dose adjustment is therefore recommended.
Paediatric population
Pharmacokinetics have been studied in children aged 4 months – 15 years taking capsules, granules or suspension. At 10 mg/kg on day 1 followed by 5 mg/kg on days 2-5, the C_{max} achieved is slightly lower than adults with 224 µg/l in children aged 0.6-5 years and after 3 days dosing and 383 µg/l in those aged 6-15 years. The $t_{1/2}$ of 36h in the older children was within the expected range for adults.

5.3 Preclinical safety data

In animal studies using exposures 40 times those achieved at the clinical therapeutic dosages, AZID was found to have caused reversible phospholipidosis, but as a rule there were no associated toxicological consequences. The relevance of this finding to humans receiving AZID in accordance with the recommendations is unknown.
Electrophysiological investigations have shown that AZID prolongs the QT interval.
Carcinogenic potential
Long-term studies in animals have not been performed to evaluate carcinogenic potential.
Mutagenic potential
There was no evidence of a potential for genetic and chromosome mutations in *in vivo* and *in vitro* test models.
Reproductive toxicity
No teratogenic effects were observed in embryotoxicity studies in rats after oral administration of AZID. In rats, AZID dosages of 100 and 200 mg/kg body weight/day led to mild retardations in fetal ossification and in maternal weight gain. In peri- and postnatal studies in rats, mild retardations following treatment with 50 mg/kg/day AZID and above were observed.

6. Pharmaceutical particulars

6.1 List of excipients

- calcium hydrogen phosphate anhydrate
- croscarmellose sodium
- pregelatinized starch
- copovidone
- sodium lauryl sulfate
- colloidal silica
- magnesium stearate.

Film: Opadry II white, purified water.

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

Box of 6 (6 x 250 mg) film-coated tablets (white, eaqual, oblong, film-coated with breake line on on side) of 250 mg azithromycin in blister pack

Box of 3 (3 x 500 mg) film-coated tablets (white, eaqual, film-coated) of 500 mg azitromicina azithromycin in blister pack

6.6 Special precautions for disposal and other handling

Any unused product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder

ZADA Pharmaceuticals Ltd.
Donji Bistarac, Lukavac, Bosna and Herzegovina

8. Marketing authorisation number(s)

Azid, film-coated tablet, 6 x 250 mg: 04-07.3-2-438/16 od 22.03.2017.
Azid, film-coated tablet, 3 x 500 mg: 04-07.3-2-439/16 od 22.03.2017.

9. Date of first authorisation/renewal of the authorisation

Azid, film-coated tablet, 6 x 250 mg: 22.03.2017.
Azid, film-coated tablet, 3 x 500 mg: 22.03.2017.

10. Date of revision of the text

20 February 2019